N-(4-methoxyphenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine | 145448-33-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: N-(4-methoxyphenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine
• 英文别名: 4-(4-methoxyanilino)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine；N-(4-methoxyphenyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidin-4-amine；N-(4-methoxyphenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-amine
• CAS: 145448-33-5
• 化学式: C₁₇H₁₇N₃OS
• 分子量: 311.407
• InChiKey: QQWDRGLVAXVWSS-UHFFFAOYSA-N

物化性质

• 熔点：
  145-147 °C
• 沸点：
  524.2±50.0 °C(Predicted)
• 密度：
  1.317±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  75.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5,6,7,8-四氢-[1]-苯并噻吩[2,3-d]嘧啶-4(1h)-酮 在 三乙胺 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 8.5h， 生成 N-(4-methoxyphenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  噻吩并[2,3-d]嘧啶衍生物作为EGFR / HER2双重抑制剂和细胞凋亡诱导剂的设计，合成和抗癌评估。

  摘要：

  许多激酶的失调与癌症的发展直接相关，酪氨酸激酶家族是当前癌症治疗方案中最重要的靶标之一。在这项研究中，我们设计并合成了一系列噻吩并[2,3-d]嘧啶衍生物，作为EGFR和HER2酪氨酸激酶抑制剂。在体外评估所有合成的化合物对EGFRWT的抑制活性。并测试了对EGFRWT表现出有希望的IC50值的最具活性的化合物对突变EGFRT790M和HER2激酶的抑制活性。此外，测试了这些化合物对四种癌细胞系（HepG2，HCT-116，MCF-7和A431）的抗肿瘤活性。化合物13g，13h和13k对所检查的细胞系表现出最高活性，IC50值为7.592±0。相当于厄洛替尼的32至16.006±0.58 µM（IC50为4.99±0.09至13.914±0.36 µM）。此外，选择了最有效的抗肿瘤药（13k）进行进一步研究，以确定其对MCF-7细胞系中细胞周期进程和细胞凋亡的影响。结果表明，该化合物阻滞了细胞周期的G2

  DOI：

  10.1016/j.bioorg.2019.102944

文献信息

• Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors
  作者：Brad E. Sleebs、George Nikolakopoulos、Ian P. Street、Hendrik Falk、Jonathan B. Baell

  DOI：10.1016/j.bmcl.2011.07.050

  日期：2011.10

  4-Aminobenzothieno[3,2-d]pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5,6-substituted 4-aminothieno[2,3-d]pyrimidines with low micromolar inhibition of LIMK1.

  4-氨基苯并噻吩并[3,2- d ]嘧啶先前在高通量筛选活动中被鉴定为LIMK1抑制剂。支架逆转导致鉴定了一系列简单的5,6-取代的4-氨基噻吩并[2,3- d ]嘧啶，对LIMK1的抑制作用很小。
• Microwave-based synthesis of novel thienopyrimidine bioisosteres of gefitinib
  作者：Manisha S. Phoujdar、Muthu K. Kathiravan、Jitender B. Bariwal、Anamik K. Shah、Kishor S. Jain

  DOI：10.1016/j.tetlet.2007.11.135

  日期：2008.2

  A series of novel 2-unsubstituted 4-(substituted)anilinothieno[2,3-d]pyrimidines is synthesized through the chlorination of the corresponding 2-unsubstituted-thieno[2,3-d]-pyrimidin-4-ones, followed by the nucleophilic displacement of the 4-Cl group of 9, with a variety of anilines. All four steps of this synthesis involve microwave irradiation (MWI) and the entire synthesis requires only 2 h. (c) 2007 Elsevier Ltd. All rights reserved.
• Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells
  作者：Stéphane Pédeboscq、Denis Gravier、Françoise Casadebaig、Geneviève Hou、Arnaud Gissot、Francesca De Giorgi、François Ichas、Jean Cambar、Jean-Paul Pometan

  DOI：10.1016/j.ejmech.2010.02.032

  日期：2010.6

  The receptor tyrosine kinases (for example EGFR, PDGFR, VEGFR) are a transmembrane protein family which plays a crucial role in tumor growth, survival, metastasis dissemination and angiogenesis. During the past 10 years, many tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment (imatinib, gefitinib, erlotinib, sunitinib, sorafenib). These compounds generally possess a pyrrolo- or pyrimido- pyrimidine scaffold or approaching molecular structure. We synthesized 10 thienopyrimidine compounds (including 5 newly synthesized) whose scaffold is very similar to the agents cited above. The cytotoxicity of these agents was evaluated using a MTT assay and a flow cytometry technique on glioblastoma cell lines. Two compounds showed a similar cytotoxicity to the standard anti-EGFR gefitinib (IC50: gefitinib = 51.9 mu M, 6b = 61.8 mu M, 6c = 41.2 mu M), suggesting a blockade of the EGFR pathway by binding to the TK receptor.
• A Microwave-Enhanced Synthesis and Biological Evaluation of N-Aryl‑5,6,7,8‑tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amines
  作者：Qing Han、Zijian Yin、Jingjiao Sui、Qingming Wang、Yaquan Sun

  DOI：10.21577/0103-5053.20190044

  日期：——
• Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
  作者：Souad A. Elmetwally、Khaled F. Saied、Ibrahim H. Eissa、Eslam B. Elkaeed

  DOI：10.1016/j.bioorg.2019.102944

  日期：2019.7

  tyrosine kinase family is one of the most important targets in current cancer therapy regimens. In this study, we have designed and synthesized a series of thieno[2,3-d]pyrimidine derivatives as an EGFR and HER2 tyrosine kinase inhibitors. All the synthesized compounds were evaluated in vitro for their inhibitory activities against EGFRWT; and the most active compounds that showed promising IC50 values

  许多激酶的失调与癌症的发展直接相关，酪氨酸激酶家族是当前癌症治疗方案中最重要的靶标之一。在这项研究中，我们设计并合成了一系列噻吩并[2,3-d]嘧啶衍生物，作为EGFR和HER2酪氨酸激酶抑制剂。在体外评估所有合成的化合物对EGFRWT的抑制活性。并测试了对EGFRWT表现出有希望的IC50值的最具活性的化合物对突变EGFRT790M和HER2激酶的抑制活性。此外，测试了这些化合物对四种癌细胞系（HepG2，HCT-116，MCF-7和A431）的抗肿瘤活性。化合物13g，13h和13k对所检查的细胞系表现出最高活性，IC50值为7.592±0。相当于厄洛替尼的32至16.006±0.58 µM（IC50为4.99±0.09至13.914±0.36 µM）。此外，选择了最有效的抗肿瘤药（13k）进行进一步研究，以确定其对MCF-7细胞系中细胞周期进程和细胞凋亡的影响。结果表明，该化合物阻滞了细胞周期的G2